Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.
One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more
Improving the diversity of enrollment in clinical trials may improve health disparities among women with ovarian cancer, according to study results presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
“Our study is evidence that no one … Read more
A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more
Driving research and awareness by working together are ways in which the word cure might one day be heard in the ovarian cancer community. Members of the tight knit “teal army” gathered last night for the inaugural Ovarian Cancer Heroes … Read more
Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more
A vaccine derived from a patient’s tumor cells, which enhances T-cell targeting of cancer cells, has shown promise against ovarian cancer.
This outcome of a phase 1 clinical trial was reported at the Society of Gynecologic Oncology’s 2018 Annual Meeting … Read more
A sample obtained from routine Papanicolaou (Pap) tests used for cervical cancer screening can be subjected to a multiplex panel test, dubbed PapSEEK, to determine whether the sample is positive for endometrial or ovarian cancer, two gynecologic cancers for which … Read more
Despite showing an interest in clinical trials and biobanking, underserved populations appear to be unclear on how to learn about them, while community physicians reported lacking appropriate information to give them, according to data to be presented at the American … Read more
The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit.
The Centers for Medicare & Medicaid … Read more
Anna Hargrove learned she carries a genetic mutation that predisposes women toward breast and ovarian cancer at 27, which was no surprise given her family history.
Hargrove, cautious by nature, did what a lot of women with the mutation do: … Read more
Use of tests that assess genomic variants in circulating tumor DNA (ctDNA) is on the rise. A new joint review from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) provides an assessment of evidence … Read more
“Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.
“The importance of early stage trials is … Read more
By: Annette McElhiney
I just turned 77 years old. As a 9 1/2 year ovarian cancer survivor, in the last 9 years I’ve particularly treasured each year I have lived. But I also realize many more years lie behind me … Read more
By: Kristie Kahl
After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian … Read more
No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment.
The women, strangers to one another living in different countries, asked their … Read more
Scientists studying ovarian cancer have revealed a new genetic mutation that increases a woman’s risk of ovarian cancer — and it can be passed to her by her father.
Recently, Medical News Today covered a study that looked into whether … Read more
By: Susan Gubar
Ongoing breakthroughs in cancer care involve personalized medicine, we are often informed. Because every malignancy is unique in terms of its genetics and genomics, one size (or protocol) cannot fit all.
A diagnosis of multiple myeloma, cancer … Read more
Women should not undergo screening for ovarian cancer if they do not have signs or symptoms of the disease, as it does not improve survival but may expose women unnecessarily to surgical complications. This is the final guidance from the … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
